

Dear Reviewers,

Thank you for your attention to my manuscript.

As you said, it was a rare case report. Nowadays, more and more *ALK*-positive lung adenocarcinoma patients are administered crizotinib for tumor shrinkage. The method of using crizotinib more safely and reliably is a thoughtful problem.

We hope physicians can pay more attention to crizotinib-induced hepatotoxicity, and prevent acute fatal liver failure. There is an important clinical significance. I think it's also what you expect.

Thank you very much!

Yours truly

Ying Zhang

February 24, 2019.